The end of Twitter? June 2023 Drug Approvals, Ozempic & More!

The end of Twitter? June 2023 Drug Approvals, Ozempic & More!

What's New This Week?

  1. The?insight?behind the?platform:?Threads?vs. Twitter
  2. The?data?behind the?approval: June 2023 breakthrough drugs
  3. Patsnap?updates: Ozempic webinar, companies 5 companies pioneering cancer research

The?Insight?Behind the?Platform: Threads?vs. Twitter

Meta Platforms' latest launch, Threads, has taken the tech world by storm, surpassing the rapid user sign-up rate of ChatGPT. The challenge now lies in retaining this massive user base.

Threads has already attracted over 100 million users within a short span since its recent launch. This impressive milestone positions Threads as a formidable contender to dethrone Elon Musk's Twitter as the go-to microblogging app.

But, will it happen?

Here's a look at the competitive landscape between these two companies:?

No alt text provided for this image

Competitive Landscape Meta Platforms, Inc. and X Corp.,?Patsnap Discovery

No alt text provided for this image

Market Cap Meta Platforms, Inc. and X Corp.,?Patsnap Discovery


No alt text provided for this image

Portfolio Size, Meta Platforms, Inc. and X Corp.,?Patsnap Discovery

No alt text provided for this image

With Threads gaining remarkable traction, the focus now shifts to user engagement and retention. Can Threads keep its newfound audience captivated and committed and dethrone Twitter??

The verdict is still out, but Elon isn't going down without a fight.?


The?Data?Behind the?Approval: June 2023 Breakthrough Drugs

June 2023 was a busy month for drug approvals, with 14 new drugs getting the green light. These new approvals include seven small molecule drugs (SMD), one monoclonal antibody (mAb), one enzyme, 1 CAR-T, one FcRN, one cell therapy, one micro-dystrophin, and one traditional Chinese medicine.

No alt text provided for this image

June 2023 Global Approved Drugs, Synapse?

58 drugs were under?expedited review pathways. The designations include:

  • 32 orphan drugs
  • 12 fast track
  • 9 priority review
  • 4 breakthrough therapy
  • 2 accelerated approval
  • 1 qualified infectious disease product
  • 1?PRIME

No alt text provided for this image

June 2023 Global Drugs Subject to Expedited Review, Synapse?

To learn more about the recent approvals, download our?June 2023 Global Drug Report.


What's New at PatSnap

5 Companies Pioneering Cancer Research

In 2022, the global investment in cancer research?reached a staggering $193 billion,?reflecting the immense dedication and resources committed to unraveling the mysteries of this complex disease. And for good reason — every?sixth death?worldwide is attributed to cancer.??

In this article, we’ll explore what cancer research is and highlight five companies pioneering the future of this devastating disease.??

Continue Reading


Understanding Ozempic: The Weight Loss Wonder and Biologic Breakthrough

Ozempic is creating a buzz! Join our webinar,?Understanding Ozempic: The Weight Loss Wonder and Biologic Breakthrough, on?Thursday, July 27th at 11 am EST?to uncover the secrets behind its success!

During the webinar, we'll explore:

?? The patents, sequences, and targets connected to semaglutide

?? Key players and their IP

?? Real-life case studies showcasing the power of semaglutide

Spaces are limited - reserve your spot today!

Register Now


要查看或添加评论,请登录

Patsnap的更多文章

社区洞察

其他会员也浏览了